Promoting Safe and Effective Genetic Testing in the United States
Neil A. Holtzman
Sold by Rarewaves USA, OSWEGO, IL, U.S.A.
AbeBooks Seller since June 10, 2025
New - Soft cover
Condition: New
Ships within U.S.A.
Quantity: 1 available
Add to basketSold by Rarewaves USA, OSWEGO, IL, U.S.A.
AbeBooks Seller since June 10, 2025
Condition: New
Quantity: 1 available
Add to basketDespite remarkable progress, much remains unknown about the risks and benefits of genetic testing. No effective interventions are yet available to improve the outcome of most inherited diseases; negative test results might not rule out future occurrence of disease, and positive test results do not necessarily mean the disease will inevitably develop. In view of this uncertainty, the Working Group on Ethical, Legal, and Social Implications of Human Genome Research at the National Institutes of Health and Department of Energy created the Task Force on Genetic Testing. Comprising representatives of fifteen major stakeholders in genetic testing and five government agencies involved with testing, the task force was charged with reviewing genetic testing in the United States and making recommendations to ensure the development of safe and effective genetic tests. In Promoting Safe and Effective Genetic Testing in the United States the members of this task force present the conclusions of their study. They begin by describing general principles involved in genetic testing, including informed consent, testing of children, confidentiality, and discrimination.They describe methods and policies to ensure the safety and effectiveness of new genetic tests, including criteria for developing tests and ways of ensuring compliance with those criteria. They then discuss how to ensure the quality of laboratories that perform genetic tests, including the role of laboratory personnel and methods of monitoring laboratory performance. They show how health care professionals outside the field of genetics can better understand the uses of genetic testing, and offer suggestions for changes in these professionals' education and training. Finally, they offer a look at testing for rare inherited genetic disorders. Members of the Task Force: Neil A. Holtzman, M.D., M.P.H. * Michael S. Watson, Ph.D., F.A.C.M.G. * Patricia A. Barr * David R. Cox, M.D., M.P.H. * Jessica G. Davis, M.D. * Stephen I. Goodman, M.D., M.Sc. * Wayne W. Grody, M.D., Ph.D. * Arthur L. Levin, M.D. * J. Alexander Lowden, M.D., Ph.D. * Patricia D. Murphy, Ph.D. * Patricia J. Numan, M.D. * Victoria O. Odesina, R.N., Sc.M., M.S. * Nancy Press, Ph.D. * Katherine A. Schneider, M.P.H. * David B. Singer * Steven Gutman, M.D., * Muin J. Khoury, M.D., Ph.D. * David Lanier, M.D. * Linda R.Lebovic * Jane S. Lin-Fu, M.D.
Seller Inventory # LU-9780801859724
Despite remarkable progress, much remains unknown about the risks and benefits of genetic testing. No effective interventions are yet available to improve the outcome of most inherited diseases; negative test results might not rule out future occurrence of disease, and positive test results do not necessarily mean the disease will inevitably develop. In view of this uncertainty, the Working Group on Ethical, Legal, and Social Implications of Human Genome Research at the National Institutes of Health and Department of Energy created the Task Force on Genetic Testing. Comprising representatives of fifteen major stakeholders in genetic testing and five government agencies involved with testing, the task force was charged with reviewing genetic testing in the United States and making recommendations to ensure the development of safe and effective genetic tests.
In Promoting Safe and Effective Genetic Testing in the United States the members of this task force present the conclusions of their study. They begin by describing general principles involved in genetic testing, including informed consent, testing of children, confidentiality, and discrimination. They describe methods and policies to ensure the safety and effectiveness of new genetic tests, including criteria for developing tests and ways of ensuring compliance with those criteria. They then discuss how to ensure the quality of laboratories that perform genetic tests, including the role of laboratory personnel and methods of monitoring laboratory performance. They show how health care professionals outside the field of genetics can better understand the uses of genetic testing, and offer suggestions for changes in these professionals' education and training. Finally, they offer a look at testing for rare inherited genetic disorders.
Members of the Task Force: Neil A. Holtzman, M.D., M.P.H. • Michael S. Watson, Ph.D., F.A.C.M.G. • Patricia A. Barr • David R. Cox, M.D., M.P.H. • Jessica G. Davis, M.D. • Stephen I. Goodman, M.D., M.Sc. • Wayne W. Grody, M.D., Ph.D. • Arthur L. Levin, M.D. • J. Alexander Lowden, M.D., Ph.D. • Patricia D. Murphy, Ph.D. • Patricia J. Numan, M.D. • Victoria O. Odesina, R.N., Sc.M., M.S. • Nancy Press, Ph.D. • Katherine A. Schneider, M.P.H. • David B. Singer • Steven Gutman, M.D., • Muin J. Khoury, M.D., Ph.D. • David Lanier, M.D. • Linda R. Lebovic • Jane S. Lin-Fu, M.D.
"About this title" may belong to another edition of this title.
Please note that we do not offer Priority shipping to any country.
We currently do not ship to the below countries:
Afghanistan
Bhutan
Brazil
Brunei Darussalam
Channel Islands
Chile
Israel
Lao
Mexico
Russian Federation
Saudi Arabia
South Africa
Yemen
Please do not attempt to place orders with any of these countries as a ship to address - they will be cancelled.
| Order quantity | 6 to 9 business days | 6 to 9 business days |
|---|---|---|
| First item | US$ 0.00 | US$ 0.00 |
Delivery times are set by sellers and vary by carrier and location. Orders passing through Customs may face delays and buyers are responsible for any associated duties or fees. Sellers may contact you regarding additional charges to cover any increased costs to ship your items.